NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Sanofi
Conditions: Chronic Rhinosinusitis With Nasal Polyps
Interventions: lunsekimig, placebo
Countries: United States, Argentina, Belgium, Bulgaria, Poland, United Kingdom
This is a parallel, Phase 2, 2-arm, multicenter, randomized, double-blind, placebo-controlled, proof-of-concept study for treatment of CRSwNP. The purpose of this study is to assess the efficacy, safety, and tolerability of add-on therapy with subcutaneous lunsekimig in adult participants (aged 18 to 70 years, inclusive) with CRSwNP who are inadequately controlled on intranasal corticosteroid treatment. Participants with and without co-morbid asthma will be included in the study, and lung function will be assessed in both groups. The study duration will be up to approximately 40 weeks per participant, including 4 weeks of screening run-in period, 24 weeks of intervention period, and 12 weeks of follow-up.
Sex: ALL
Age: 18 Years to 70 Years
Healthy volunteers: No
Study type: INTERVENTIONAL
Inclusion Criteria: \- A minimum bilateral nasal polyp score of 5 out of a maximum score of 8 for both nostrils (with at least a score of 2 for each nostril) despite use of intranasal corticosteroid treatment for at least 2 months prior to screening Ongoing symptoms for at least 2 months prior to screening, including: * Nasal congestion, blockage, or obstruction with moderate or severe symptom severity at screening (Score 2 or 3 on NC Score) and a weekly average severity score of at least 1 (range 0 to 3) at randomization (NC Score: 0=no symptoms, 1=mild, 2=moderate, and 3=severe). * At least 1 of the following 2 symptoms: (1) partial loss of smell (hyposmia) or total loss of smell (anosmia); (2) anterior and/or posterior rhinorrhea. Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply: * Patient who has received any therapies such as for example systemic corticosteroids, anti-IgE therapy, monoclonal antibody and some others in the specified timeframe(s) prior to the screening visit * Patients who have undergone any nasal/sinus surgery within 6 months before screening or for whom NPS cannot be determined accurately on endoscopy due to anatomic changes to the nasal cavity from past nasal/sinus surgery * Patients with conditions/concomitant diseases making them non evaluable for the primary efficacy endpoint * Signs or a CT scan suggestive of Allergic fungal rhinosinusitis * Active/chronic helminthic infection * History of human immunodeficiency virus (HIV) infection or positive HIV screen (Anti-HIV- and HIV-2 antibodies) at screening visit * Patients with positive or indeterminate hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or hepatitis C antibody at screening visit NOTE: The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial
- La Jolla, California, United States
- Roseville, California, United States
- San Diego, California, United States
- Tampa, Florida, United States
- Atlanta, Georgia, United States
- Boise, Idaho, United States
- Boston, Massachusetts, United States
- Tulsa, Oklahoma, United States
- Bellaire, Texas, United States
- Dallas, Texas, United States
- McKinney, Texas, United States
- San Antonio, Texas, United States
- Ogden, Utah, United States
- Norfolk, Virginia, United States
- Rosario, Santa Fe Province, Argentina
- Buenos Aires, Argentina
- Mendoza, Argentina
- Ghent, Belgium
- Leuven, Belgium
- Sofia, Bulgaria
- Krakow, Lesser Poland Voivodeship, Poland
- Warsaw, Masovian Voivodeship, Poland
- Warsaw, Masovian Voivodeship, Poland
- Katowice, Silesian Voivodeship, Poland
- Poznan, Poland
- Wroclaw, Poland
- Gloucester, Gloucestershire, United Kingdom
- Manchester, United Kingdom
- Newcastle upon Tyne, United Kingdom